Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer

BACKGROUND: New therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce durable responses in bladder cancer while maximizing T cells at the tumor s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazargan, Sarah, Bunch, Brittany, Ojwang‘, Awino Maureiq E., Blauvelt, Jamie, Landin, Annick, Ali, Johannes, Abrahams, Dominique, Cox, Cheryl, Hall, Amy M., Beatty, Matthew S., Poch, Michael, Rejniak, Katarzyna A., Pilon-Thomas, Shari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602731/
https://www.ncbi.nlm.nih.gov/pubmed/37901214
http://dx.doi.org/10.3389/fimmu.2023.1275375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602731/
https://www.ncbi.nlm.nih.gov/pubmed/37901214
http://dx.doi.org/10.3389/fimmu.2023.1275375

Ejemplares similares